Advicenne Provides an Update on Its Activities Following Its Annual General Meeting - Seite 2

In parallel, the Company is pursuing the clinical development of Sibnayal in cystinuria both in Europe and in the US, with a potential approval in first-half 2023 and second-half 2023, respectively. Sibnayal is now a largely de-risked medicine following its approval by the European Commission and the clearance of its clinical development in the US in dRTA.

The decision to prioritize capital allocation to Sibnayal is largely driven by its favorable risk / reward profile and its peak sales potential. The resources to progress the US development of Sibnayal and unlock shareholder value will partly come through a partnership to ensure Sibnayal’s commercial success in Europe as well as from the license agreement on Ozalin with Primex.

Strengthened management to lead Advicenne 2.0

With a clear new strategy and corporate goals in place, Advicenne has implemented major changes in management to align the executive team with the Company’s ambitions. The Chairman of the Board, David Solomon, is taking an expanded executive role alongside the newly appointed Chief Executive Officer, Didier Laurens. A highly recognized industry executive, Didier brings his experience in finance and investor communications, combined with his 10-year background in marketing in the pharmaceutical industry. Robbie MacCarthy joined as General Manager of Advicenne’s US subsidiary bringing extensive knowledge of the US market, clinical development, and years of experience in rare diseases and start-up organizations. He has already hired an experienced team that is committed to restart and progress ARENA-2.

Advicenne will continue to strengthen its management team by hiring highly experienced executives in medical affairs, manufacturing, and commercial operations in the near term.

Our lead product, Sibnayal, is ready to launch and the Company is committed to fully unlock the value of its lead product both in dRTA and Cystinuria and both in Europe and North America to the benefit of our shareholders. Advicenne 2.0 marks a new era for patients and shareholders.

About Advicenne

Advicenne (Euronext: ADVIC) is a pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead drug candidate is currently in late-stage clinical trials for two kidney diseases: distal renal tubular acidosis and cystinuria. ADV7103 has just received a Marketing Approval (MAA) for the treatment of dRTA. Headquartered in Paris, Advicenne has been listed on the Euronext Paris stock exchange since 2017 and was cross-listed on the Euronext Brussels stock exchange in 2019.